Impella in cardiogenic shock following acute myocardial infarction: a systematic review and meta-analysis
- 1 December 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Wiener klinische Wochenschrift
- Vol. 132 (23-24), 716-725
- https://doi.org/10.1007/s00508-020-01712-y
Abstract
Background and objective Cardiogenic shock (CS) conveys a high mortality risk. A cardiac assist device may serve as bridge to patient recovery. We aimed to provide a pooled estimate on mortality and complications from studies evaluating the use of the left ventricular assist device Impella in CS following acute myocardial infarction. In addition, we evaluated whether mortality risk differed with device placement before or after percutaneous coronary intervention (PCI). Methods We searched Medline, Embase and Web of Science from 2005 until July 2019 for observational studies or clinical trials on this specific patient group. Studies were required to report on 30-day all-cause mortality and device-related complications. We calculated pooled proportions with 95% confidence intervals (CI) using random effects models and the inverse variance method. Results Overall, 671 patients from 11 studies (2 randomized and 9 observational) were included. Pooled proportions showed a 30-day mortality of 54.6% (95% CI 47.3-61.8;P & x202f;= 0.22;I-2 & x202f;= 65.8%). Among complications, major bleeding was found in 19.9% (95% CI 14.2-27.3;P & x202f;< 0.05;I-2 & x202f;= 69.1%), hemolysis in 10.5% (95% CI 7.2-15.0;P & x202f;< 0.05;I-2 & x202f;= 52.1%), limb ischemia in 5.0% (95% CI 2.6-9.5;P & x202f;< 0.05;I-2 & x202f;= 48.3%) and stroke in 3.8% of patients (95% CI 2.4-5.9;P & x202f;< 0.05;I-2 & x202f;= 0%). Sensitivity analysis demonstrated a statistically significant risk reduction in 30-day mortality when Impella was implanted prior to PCI as compared to after PCI, risk ratio (RR): 0.71, CI 0.58-0.86,P & x202f;= 0.001,I-2 & x202f;= 0%. Conclusion Pooled estimates of Impella use in myocardial infarction with CS revealed a high 30-day mortality; however, as compared to post-PCI, Impella initiation prior to PCI was associated with a survival benefit.Keywords
This publication has 39 references indexed in Scilit:
- Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating ST‐Elevation Myocardial Infarction in the United StatesJournal of the American Heart Association, 2014
- Mechanically Unloading the Left Ventricle Before Coronary Reperfusion Reduces Left Ventricular Wall Stress and Myocardial Infarct SizeCirculation, 2013
- Percutaneous Left-Ventricular Support With the Impella-2.5–Assist Device in Acute Cardiogenic ShockCirculation: Heart Failure, 2013
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial InfarctionJournal of the American College of Cardiology, 2012
- The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspectiveJournal of Medical Economics, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: The Academic Medical Center intensive care unit experience*Critical Care Medicine, 2011
- Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trialsEuropean Heart Journal, 2009
- A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial InfarctionJournal of the American College of Cardiology, 2008
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJama-Journal Of The American Medical Association, 2000